{"disease":{"id":"recurrent-polymorphic-post-transplant-lymphoproliferative-disorder","name":"recurrent polymorphic post transplant lymphoproliferative disorder"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06723457","title":"Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT06672705","title":"Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Timothy Voorhees","has_results":false},{"nct_id":"NCT02900976","title":"Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Children's Oncology Group","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}